Hyperliquid Bitcoin long positions are facing $130 million in unrealized losses, with 95% of these positions underwater. The total open long exposure stands at $1.32 billion, spread across nearly 25,000 wallets, representing 67% of all BTC positions on the platform. Many longs were entered at high prices averaging $75,565, with 40% opened above $76,000, and liquidation prices averaging $52,128. Recent liquidations totaled $258 million in 24 hours, with potential liquidations increasing sharply if BTC prices fall further to $65,000, $60,000, or $55,000, signaling significant risk for long holders if prices decline.
The story on Hyperliquid Bitcoin longs facing significant unrealized losses provides context for cryptocurrency market conditions. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 13, 2026 12:51 WIB: out of 50 priced major cryptocurrencies, 8 rose and 41 fell today. Bitcoin (BTC) traded at Rp1.251.791.339 with a 1-day change of -6.05%, a typical hold time of 113 days, and Pluang order activity showing 27% sell and 73% buy. AAVE and ZIL also declined by 6.47% and 5.84% respectively.
The 9th Shandong-South Korea Economic and Trade Cooperation Conference and Yantai South Korea Week began on November 6 in Yantai, Shandong Province, highlighting strong economic ties between Shandong and South Korea. Over 150 enterprises participated...
Bitcoin plunged to a nearly three-month low of $67,500 on November 12, extending its November losses beyond 11%, driven by heavy sell-offs and market uncertainty following the ouster of Nvidia's CEO. Crypto liquidations surged to $1.62 billion, with ...
South Korean crypto exchange Upbit has temporarily suspended deposits and withdrawals of Osmosis (OSMO) following a network-wide stall where the Osmosis blockchain stopped producing new blocks at height 74,955,152 on November 12, 2026. Despite this, ...
First Phosphate Corp. is reaffirmed as a speculative Buy due to its strong balance sheet and significant government and export credit support, including a $212.5M SERV letter. The company’s Bégin Lamarche project is supported by these financial stren...
4D Molecular Therapeutics reported a wider adjusted loss of $1.08 per share for Q3 2026, missing analyst expectations. However, the company's revenue reached $4.15 million, surpassing both estimates and last year's figures, continuing a trend of stro...
